Topic:

M&A

Latest Headlines

Latest Headlines

Bigger pharma may be scraping for good deals, but Horizon has plenty of options, analysts say

Horizon Pharma isn't exactly the only specialty pharma company hunting for deals. Allergan, Mallinckrodt, Endo and the ever-acquisitive Valeant have all been on shopping sprees lately, leaving some analysts wondering just what's left worth buying in the space.

Will Mylan boost its Perrigo bid? New securities filing suggests it won't

Perrigo was none too fond of Mylan's most recent offer when it made it back in April. Yet it looks like that's the one Mylan's sticking with--at least for now.

UPDATED: Investors erase Zoetis gains as questions emerge about Valeant's pursuit

Just one day after the Wall Street Journal reported that Valeant had made a buyout bid for Zoetis, sending shares of the animal health giant up 11% to an all-time high of $55.48, investors started doubting the deal would happen. As of Monday's stock market opening, no details about the acquisition attempt had been released, and shares opened trading at just over $48--erasing all the gains that had come from the rumor.

Celladon pulls the plug on R&D after a crushing gene therapy failure

Celladon is circling the drain, suspending all research tied to its failed gene therapy and again halving its payroll as management searches for a sale and flirts with liquidation.

Valeant makes offer for Zoetis, sources tell WSJ

Rapidly expanding Valeant has approached Zoetis about a buyout, sources told the Wall Street Journal. Rumors of a possible deal, which have been bouncing back and forth for weeks, set off buying, with Zoetis shares closing up 11% Thursday at an all-time high of $55.38.

Allergan CEO: 'The cuts are done' at layoffs-plagued Irvine campus

The good news for Allergan's ex-headquarters in Irvine, CA: CEO Brent Saunders says the operations there are still key to the company. More good news: The layoffs that hit that site are now over and done, he says.

CAR-T's explosion puts Juno and Kite under the M&A spotlight

The promise of new treatments that use the body's own immune cells to fight cancer has sent soaring the value of a handful of biotech startups, and analysts say Big Pharma may be waiting in the wings with buyout offers as the science continues to progress.

Generics maker Alvogen eyes faster growth after CVC-led buyout

A group of investment funds has teamed up to buy generics maker Alvogen. A consortium led by CVC Capital Partners snapped up a majority stake in the NJ-based company, in a deal valuing Alvogen at $2 billion.

Patterson closes on $1.1B deal for Animal Health International, doubling size of its vet unit

Patterson Companies, a Minnesota-based production and animal health distribution company, completed its $1.1 billion acquisition of Animal Health International in a deal that doubles the size of the company's veterinary unit.

Teva ratchets up its M&A pressure on Mylan with larger stake

Teva has upped its Mylan stake yet again--this time, passing a critical threshold that could help it pose a legal challenge to its generics rival.